title: Hepatitis B reactivation in patient with non-Hodgkin's lymphoma receiving rituximab-based chemotherapy: need for education and attention.
abstract: Hepatitis B reactivation can occur in patients with inactive chronic hepatitis B receiving rituximab treatment. Therefore, hepatitis B virus (HBV) screening is recommended in patients planned for chemotherapy and antiviral prophylaxis needs to be started prior to initiating the treatment in patients with evidence of HBV infection. We describe a 58-year-old African American man with history of chronic hepatitis B who developed severe (HBV) reactivation while receiving rituximab treatment for Non-Hodgkin's lymphoma (NHL). The report highlights that greater education is needed amongst clinicians regarding risk of HBV reactivation while receiving chemotherapy, particularly with rituximab-based treatment.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Medicine, University of Arkansas for Medical Science, Little Rock, AR, USA.
authors.forename: Ju Dong
authors.initials: JD
authors.lastname: Yang
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Medicine, University of Arkansas for Medical Science, Little Rock, AR, USA.
authors.forename: Mohit
authors.initials: M
authors.lastname: Girotra
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Medicine, University of Arkansas for Medical Science, Little Rock, AR, USA.
authors.forename: Arjun
authors.initials: A
authors.lastname: Vaid
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Medicine, University of Arkansas for Medical Science, Little Rock, AR, USA.
authors.forename: Andres
authors.initials: A
authors.lastname: Duarte-Rojo
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D019694:Hepatitis B, Chronic / Q000209:etiology*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D020380:Needs Assessment; D009894:Opportunistic Infections / Q000209:etiology*; D012008:Recurrence; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab